within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BK01_Dapagliflozin;

model Dapagliflozin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.78,
    Cl = 2.5555555555555553e-06,
    adminDuration = 600,
    adminMass = 10 / 1000000,
    adminCount = 1,
    Vd = 0.118,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0115,
    Tlag = 18.0,
    Vdp = 0.055,
    k12 = 3.138888888888889e-06,
    k21 = 3.138888888888889e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Dapagliflozin</td></tr><tr><td>ATC code:</td><td>A10BK01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>10</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>118</td><td>L</td></tr>
    <tr><td>clearance:</td><td>9.2</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor approved for the treatment of type 2 diabetes mellitus. It lowers blood glucose by promoting urinary glucose excretion and has also been approved to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and established cardiovascular disease.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers (both male and female) after single oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Dhillon, S (2019). Dapagliflozin: A Review in Type 2 Diabetes. <i>Drugs</i> 79(10) 1135–1146. DOI:<a href=\"https://doi.org/10.1007/s40265-019-01148-3\">10.1007/s40265-019-01148-3</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31236801/\">https://pubmed.ncbi.nlm.nih.gov/31236801</a></p></li><li><p>Tirucherai, GS, et al., &amp; Boulton, DW (2016). Pharmacokinetics and pharmacodynamics of dapagliflozin in children and adolescents with type 2 diabetes mellitus. <i>Diabetes, obesity &amp; metabolism</i> 18(7) 678–684. DOI:<a href=\"https://doi.org/10.1111/dom.12638\">10.1111/dom.12638</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27291448/\">https://pubmed.ncbi.nlm.nih.gov/27291448</a></p></li><li><p>Naagaard, MD, et al., &amp; Boulton, DW (2022). Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. <i>British journal of clinical pharmacology</i> 88(4) 1942–1946. DOI:<a href=\"https://doi.org/10.1111/bcp.15117\">10.1111/bcp.15117</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34687551/\">https://pubmed.ncbi.nlm.nih.gov/34687551</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.A.A10BK01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Dapagliflozin;
